Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Caribou Biosciences, Inc.

< Previous 1 2 Next >
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Proposed Public Offering of Common Stock
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU PFE
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Tickers CRBU
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.